Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-001069957 plus low-dose aspirin versus celecoxib plus aspirin or aspirin alone for gastroduodenal ulcer incidence in osteoarthritis or rheumatoid arthritis
2004-000612-54Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JTE-522 in osteoarthritis (OA) and rheumatoid arthritis (RA) (4 arms), sponsored by Merck & Co. Primary endpoint: Development of gastric and/or duodenal ulcers. Started Jul 2004; status: completed.
02
Drugs
JTE-522
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2004-000612-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000612-54.